204 related articles for article (PubMed ID: 24405254)
1. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
[TBL] [Abstract][Full Text] [Related]
3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
4. International differences in companion diagnostic approvals: how are we able to manage the differences?
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2015 Feb; 15(2):157-9. PubMed ID: 25308218
[TBL] [Abstract][Full Text] [Related]
5. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
6. Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan.
Tanaka A; Suzuki H; Toyoshima S; Nagai N
Ther Innov Regul Sci; 2022 Jan; 56(1):85-95. PubMed ID: 34406635
[TBL] [Abstract][Full Text] [Related]
7. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
8. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
9. CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
Wise J; Furness M; McWilliams S; Patton S
Drug Discov Today; 2019 Nov; 24(11):2120-2125. PubMed ID: 31306783
[TBL] [Abstract][Full Text] [Related]
10. Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.
Hikino K; Fukunaga K; Mushiroda T
Drug Metab Pharmacokinet; 2018 Dec; 33(6):243-249. PubMed ID: 30360950
[TBL] [Abstract][Full Text] [Related]
11. Twenty-five years with companion diagnostics.
Jørgensen JT
Chin Clin Oncol; 2023 Dec; 12(6):65. PubMed ID: 37953243
[TBL] [Abstract][Full Text] [Related]
12. Companion and complementary diagnostics for infectious diseases.
Dailey PJ; Elbeik T; Holodniy M
Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
[TBL] [Abstract][Full Text] [Related]
13. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
14. Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs.
Jørgensen JT
JCO Precis Oncol; 2022 Jun; 6():e2200100. PubMed ID: 35709402
[TBL] [Abstract][Full Text] [Related]
15. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
16. Changes in Companion Diagnostic Labelling: Implementation of FDA's April 2020 Guidance for Industry for In Vitro CDx Labeling for Specific Oncology Therapeutic Groups.
Cooper L; Chen J
Ther Innov Regul Sci; 2022 Sep; 56(5):689-697. PubMed ID: 35689144
[TBL] [Abstract][Full Text] [Related]
17. Regulatory issues on breath tests and updates of recent advances on [13C]-breath tests.
Modak AS
J Breath Res; 2013 Sep; 7(3):037103. PubMed ID: 23774086
[TBL] [Abstract][Full Text] [Related]
18. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine.
Sapsford KE; Tezak Z; Kondratovich M; Pacanowski MA; Zineh I; Mansfield E
Ther Deliv; 2010 Nov; 1(5):631-41. PubMed ID: 22833953
[TBL] [Abstract][Full Text] [Related]
20. The current landscape of the FDA approved companion diagnostics.
Jørgensen JT
Transl Oncol; 2021 Jun; 14(6):101063. PubMed ID: 33714919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
